01_09a Daroxonrasib: A KRAS(on) inhibitor (mini-discussion)
1. RAS as an oncogene 2. The undruggable RAS 3. KRAS G12C as a specific exception 4. Daroxonrasib as a pan RAS(On) inhibitor Citations As always, citations, and sources include education from our re...
8 Jun 14min
05_02 Neuroendocrine Tumors
1. Nomenclature, unique considerations 2. Secretory Syndromes 3. Somatostatin directed therapy 4. Peptide Receptor Radionucleotide Therapy Citations As always, citations, and sources include education...
3 Mai 202527min
05_01 Hepatocellular carcinoma
1. Etiologies and epidemiology 2. Staging and local/regional considerations 3. Systemic Therapy 4. Differences in immune checkpoint sensitivity by etiology Citations As always, citations, and sources ...
19 Des 202432min
04_10 Testicular Cancer II
1. Stage II Disease 2. Overview of BEP, EP, VIP 3. Advanced, refractory disease 4. Survivorship considerations Citations As always, citations, and sources include education from our respective trainin...
27 Okt 202425min
04_09 Testicular Cancer I
1. Background, work up 2. Staging of seminoma and NSGCT 3. Young Adult/Adolescent Oncology 4. Management of Stage I Disease Citations As always, citations, and sources include education from our res...
18 Sep 202428min
04_08 Metastatic Renal Cell Carcinoma
1. Historical Approach (cytoreduction, IFN-a, sunitinib 2. Prognostic risk scores 3. Evidence for modern doublet regimens 4. Later line therapy Citations As always, citations, and sources include educ...
2 Aug 202424min
04_06 Metastatic Urothelial Cancer
1. Immunohistochemistry of urothelial cancer 2. History of systemic therapy in advanced and metastatic disease 3. Pembrolizumab and Enfortumab Vedotin 4. Approach to second line therapy and beyond Cit...
24 Mai 202424min
